百利天恒：2025年净利润亏损10.51亿元

Core Viewpoint - The company reported a significant decline in total revenue and net profit for the fiscal year 2025, primarily due to the recognition of a large upfront payment in the previous year that was not repeated in the current period [1] Financial Performance - Total revenue for the fiscal year 2025 was 2.52 billion yuan, representing a year-on-year decrease of 56.72% [1] - The net profit for the same period was a loss of 1.051 billion yuan, which is a year-on-year decrease of 128.34% [1] Collaboration and Milestones - The company successfully advanced its collaboration with Bristol-Myers Squibb (BMS) on the drug iza-bren (EGFR×HER3 dual antibody ADC) [1] - A key milestone was achieved in the global Phase II/III pivotal registration clinical trial IZABRIGHT-Breast01, leading to the receipt of the first milestone payment of 250 million USD, which was confirmed as revenue [1] - In the previous year, the company recognized 800 million USD in non-refundable and non-offsettable upfront payment from BMS under the same collaboration agreement, which contributed significantly to the revenue in that period [1]